Depression und Arbeitswelt

In der WHO-Charta von Ottawa aus dem Jahre 1986 steht zu lesen: >>Die Art und Weise, wie eine Gesellschaft die Arbeit und die Arbeitsbedingungen organisiert, sollte eine Quelle der Gesundheit und nicht der Krankheit sein.<< Diese Forderung ist in der spätmodernen Arbeitsgesellschaft nach wie vor nicht eingelöst. Und Erwerbsarbeit ist kein Lebensbereich wie jeder andere. Über das Einkommen sichert sie das materielle Auskommen der Gesellschaftsmitglieder und ermöglicht ihnen, sich sozial zu integrieren und zu partizipieren. Deshalb sind Arbeitsplatzunsicherheit (Sverke, Hellgren u. N ä swall, 2006) und Arbeitslosigkeit (Paulu. Moser, 2009) kritische Lebensereignisse, die kränken undkrank machen. Was die Arbeitsplatzunsicherheit betrifft, so ist es nicht allein die Sorge, den Arbeitsplatz zu verlieren, die belastet. Gleiches gilt für die verbreitete Erfahrung, dass sich die Arbeitsbedingungen der Arbeitnehmer und Arbeitnehmerinnen auf Kosten ihrer psychischen Gesundheit gravierend verschlechtern. Deshalb muss es alarmieren, wenn Besch ä ftigtenbefragungen gegenw ä rtig darauf hinweisen, dass etwa jeder Zweite seine gesundheitlichen Probleme in einen ursächlichen Zusammenhang mit den Arbeitsbedingungen an seinem Arbeitsplatz bringt (Zok, 2010)

Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors

BACKGROUND: Tuberculosis (TB) still presents a leading cause of morbidity and mortality among people living with HIV/AIDS (PLWHA), including those on antiretroviral therapy. In this study, we aimed to determine the long-term incidence density rate (IDR) of TB and risk factors among PLWHA in relation to combination antiretroviral therapy (cART)-status. METHODS: Data of PLWHA enrolled from 2001 through 2011 in the German ClinSurv HIV Cohort were investigated using survival analysis and Cox regression. RESULTS: TB was diagnosed in 233/11,693 PLWHA either at enrollment (N = 62) or during follow-up (N = 171). The TB IDR during follow-up was 0.37 cases per 100 person-years (PY) overall [95% CI, 0.32-0.43], and was higher among patients who never started cART and among patients originating from Sub-Saharan Africa (1.23 and 1.20 per 100PY, respectively). In two multivariable analyses, both patients (I) who never started cART and (II) those on cART shared the same risk factors for TB, namely: originating from Sub-Saharan Africa compared to Germany (I, hazard ratio (HR); [95% CI]) 4.05; [1.87-8.78] and II, HR 5.15 [2.76-9.60], CD4+ cell count <200 cells/μl (I, HR 8.22 [4.36-15.51] and II, HR 1.90 [1.14-3.15]) and viral load >5 log(10) copies/ml (I, HR 2.51 [1.33-4.75] and II, HR 1.77 [1.11-2.82]). Gender, age or HIV-transmission risk group were not independently associated with TB. CONCLUSION: In the German ClinSurv HIV cohort, patients originating from Sub-Saharan Africa, with low CD4+ cell count or high viral load at enrollment were at increased risk of TB even after cART initiation. As patients might be latently infected with Mycobacterium tuberculosis complex, early screening for latent TB infection and implementing isoniazid preventive therapy in line with available recommendations is crucial

Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (nash) in five european countries in 2018: A cost-of-illness analysis.

BACKGROUND AND AIMS Non-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom (UK) in 2018. METHODS The socioeconomic burden of diagnosed NASH was estimated using cost-of-illness methodology applying a prevalence approach to estimate the number of adults with NASH and the attributable economic and wellbeing costs. Given undiagnosed patients do not incur costs in the study, the probability of diagnosis is central to cost estimation. The analysis was based on literature review, databases and consultation with clinical experts, economists and patient groups. RESULTS The proportion of adult NASH patients with a diagnosis ranged from 11.9% to 12.7% across countries, which increased to 38.8% to 39.1% for advanced fibrosis (F3 to F4 compensated cirrhosis). Total economic costs were €8,548-19,546M. Of these, health system costs were €619-1,292M. Total wellbeing costs were €41,536-90,379M. The majority of the undiagnosed population (87.3% to 88.2% of total prevalence) was found to have early stage NASH which, left untreated, may progress to more resource consuming ESLD over time. CONCLUSIONS This study found the majority of economic and wellbeing costs of NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients could reduce future healthcare costs